Skip to main content
SpringerLink
Log in

Menopause Symptoms

  • Chapter
  • First Online:
The MASCC Textbook of Cancer Supportive Care and Survivorship

Abstract

The menopause transition, particularly if it occurs as a result of cancer treatment earlier than expected, can be distressing and have long term negative consequences for one’s quality of life. Several important symptoms such as hot flashes, osteroporosis and vulvovaginal symptoms are discussed in terms of physiology and evidence based treatments. Appropriate assessment and management can add positively to women’s quality of survivorship. More research is needed to identify efficient treatment algorithms for symptoms related to estrogen deprivation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Gracia CR, Freeman EW. Acute consequences of the menopausal transition: the rise of common menopausal symptoms. Endocrinol Metab Clin North Am. 2004;33(4):675–89.

    Article  CAS  PubMed  Google Scholar 

  2. Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol. 1999;17(8):2365–70.

    Article  CAS  PubMed  Google Scholar 

  3. National Institutes of Health State-of-the-Science Conference statement: management of menopause-related symptoms. Ann Internal Med. 2005;142(12 Pt 1):1003–13.

    Google Scholar 

  4. Hunter M, Rendall M. Bio-psycho-socio-cultural perspectives on menopause. Best Pract Res Clin Obstet Gynaecol. 2007;21(2):261–74.

    Article  PubMed  Google Scholar 

  5. Hunter MS, Grunfeld EA, Mittal S, et al. Menopausal symptoms in women with breast cancer: prevalence and treatment preferences. Psychooncology. 2004;13(11):769–78.

    Article  PubMed  Google Scholar 

  6. Poniatowski BC, Grimm P, Cohen G. Chemotherapy-induced menopause: a literature review. Cancer Invest. 2001;19(6):641–8.

    Article  CAS  PubMed  Google Scholar 

  7. Fallowfield L. Quality of life issues in relation to the aromatase inhibitor. J Steroid Biochem Mol Biol. 2007;106(1–5):168–72.

    Article  CAS  PubMed  Google Scholar 

  8. Bernhard J, Luo W, Ribi K, et al. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Lancet Oncol. 2015;16(7):848–58.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol. 2001;19(14):3306–11.

    Article  CAS  PubMed  Google Scholar 

  10. Lester J, Dodwell D, Mccloskey E, Coleman R. The causes and treatment of bone loss associated with carcinoma of the breast. Cancer Treat Rev. 2005;31(2):115–42.

    Article  PubMed  Google Scholar 

  11. Kuzmarov IW, Bain J. Sexuality in the aging couple, part I: the aging woman. Geriatr Aging. 2009;11(10):589–94.

    Google Scholar 

  12. Goss PE, Ingle JN, Pritchard KI, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med. 2016;375(3):209–19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Notelovitz M. Menopause. Totowan, NJ: Humana Press; 2000.

    Book  Google Scholar 

  14. Gallicchio L, Whiteman MK, Tomic D, Miller KP, Langenberg P, Flaws JA. Type of menopause, patterns of hormone therapy use, and hot flashes. Fertil Steril. 2006;85(5):1432–40.

    Article  PubMed  Google Scholar 

  15. Edwards D, Panay N. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition? Climacteric. 2016;19(2):151–61.

    Article  CAS  PubMed  Google Scholar 

  16. Greendale GA, Lee NP, Arriola ER. The menopause. Lancet. 1999;353(9152):571–80.

    Article  CAS  PubMed  Google Scholar 

  17. Carpenter JS, Johnson D, Wagner L, Andrykowski M. Hot flashes and related outcomes in breast cancer survivors and matched comparison women. Oncol Nurs Forum. 2002;29(3):E16–25.

    Article  PubMed  Google Scholar 

  18. Freedman RR, Woodward S. Core body temperature during menopausal hot flushes. Fertil Steril. 1996;65(6):1141–4.

    Article  CAS  PubMed  Google Scholar 

  19. Berendsen H. Hot flushes and serotonin. Br Menopause Soc J. 2002;8:30–4.

    Article  Google Scholar 

  20. Shanafelt TD, Barton DL, Adjei AA, Loprinzi CL. Pathophysiology and treatment of hot flashes. Mayo Clin Proc. 2002;77(11):1207–18.

    Article  CAS  PubMed  Google Scholar 

  21. De Zambotti M, Colrain IM, Sassoon SA, Nicholas CL, Trinder J, Baker FC. Vagal withdrawal during hot flashes occurring in undisturbed sleep. Menopause. 2013;20(11):1147–53.

    Article  PubMed  Google Scholar 

  22. Thurston RC, Christie IC, Matthews KA. Hot flashes and cardiac vagal control during women’s daily lives. Menopause. 2012;19(4):406–12.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Freedman RR, Dinsay R. Clonidine raises the sweating threshold in symptomatic but not in asymptomatic postmenopausal women. Fertil Steril. 2000;74(1):20–3.

    Article  CAS  PubMed  Google Scholar 

  24. Freedman RR, Krell W. Reduced thermoregulatory null zone in postmenopausal women with hot flashes. Am J Obstet Gynecol. 1999;181(1):66–70.

    Article  CAS  PubMed  Google Scholar 

  25. Loprinzi CL, Sloan J, Stearns V, et al. Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis. J Clin Oncol. 2009;27(17):2831–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Loprinzi CL, Qin R, Balcueva EP, et al. Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1. J Clin Oncol. 2010;28(4):641–7.

    Article  CAS  PubMed  Google Scholar 

  27. Rada G, Capurro D, Pantoja T, et al. Non-hormonal interventions for hot flushes in women with a history of breast cancer. Cochrane Database Syst Rev. 2010;(9):Cd004923. https://doi.org/10.1002/14651858.CD004923.pub2.

  28. Freeman EW, Guthrie KA, Caan B, et al. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA. 2011;305(3):267–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Kimmick GG, Lovato J, Mcquellon R, Robinson E, Muss HB. Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. Breast J. 2006;12(2):114–22.

    Article  PubMed  Google Scholar 

  30. Barton D, Loprinzi C, Atheron P, et al. Pilot trial of desipramine for the control of hot flashes (abstract P-42). Menopause. 2006;13(6):1002.

    Google Scholar 

  31. Perez DG, Loprinzi CL, Sloan J, et al. Pilot evaluation of bupropion for the treatment of hot flashes. J Palliat Med. 2006;9(3):631–7.

    Article  PubMed  Google Scholar 

  32. Loprinzi CL, Stearns V, Barton D. Centrally active nonhormonal hot flash therapies. Am J Med. 2005;118(Suppl 12B):118–23.

    Article  PubMed  Google Scholar 

  33. Barton D, Loprinzi CL. Making sense of the evidence regarding nonhormonal treatments for hot flashes. Clin J Oncol Nurs. 2004;8(1):39–42.

    Article  PubMed  Google Scholar 

  34. Ziaei S, Kazemnejad A, Zareai M. The effect of vitamin E on hot flashes in menopausal women. Gynecol Obstet Invest. 2007;64(4):204–7.

    Article  CAS  PubMed  Google Scholar 

  35. Quella SK, Loprinzi CL, Barton DL, et al. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: a North Central Cancer Treatment Group Trial. J Clin Oncol. 2000;18(5):1068–74.

    Article  CAS  PubMed  Google Scholar 

  36. St Germain A, Peterson CT, Robinson JG, Alekel DL. Isoflavone-rich or isoflavone-poor soy protein does not reduce menopausal symptoms during 24 weeks of treatment. Menopause. 2001;8(1):17–26.

    Article  CAS  PubMed  Google Scholar 

  37. Van Patten CL, Olivotto IA, Chambers GK, et al. Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized, controlled clinical trial. J Clin Oncol. 2002;20(6):1449–55.

    Article  PubMed  Google Scholar 

  38. Huntley AL, Ernst E. Soy for the treatment of perimenopausal symptoms—a systematic review. Maturitas. 2004;47(1):1–9.

    Article  PubMed  Google Scholar 

  39. Newton KM, Reed SD, Lacroix AZ, Grothaus LC, Ehrlich K, Guiltinan J. Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial. Ann Intern Med. 2006;145(12):869–79.

    Article  PubMed  Google Scholar 

  40. Pockaj BA, Gallagher JG, Loprinzi CL, et al. Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG trial N01CC1. J Clin Oncol. 2006;24(18):2836–41.

    Article  PubMed  Google Scholar 

  41. Pruthi S, Thompson SL, Novotny PJ, et al. Pilot evaluation of flaxseed for the management of hot flashes. J Soc Integr Oncol. 2007;5(3):106–12.

    Article  PubMed  Google Scholar 

  42. Lethaby A, Marjoribanks J, Kronenberg F, Roberts H, Eden J, Brown J. Phytoestrogens for menopausal vasomotor symptoms. Cochrane Database Syst Rev. 2013;(12):Cd001395. https://doi.org/10.1002/14651858.CD001395.pub4.

  43. Lee MS, Kim JI, Ha JY, Boddy K, Ernst E. Yoga for menopausal symptoms: a systematic review. Menopause. 2009;16(3):602–8.

    Article  PubMed  Google Scholar 

  44. Daley AJ, Stokes-Lampard HJ, Macarthur C. Exercise to reduce vasomotor and other menopausal symptoms: a review. Maturitas. 2009;63(3):176–80.

    Article  CAS  PubMed  Google Scholar 

  45. Whitcomb BW, Whiteman MK, Langenberg P, Flaws JA, Romani WA. Physical activity and risk of hot flashes among women in midlife. J Womens Health (Larchmt). 2007;16(1):124–33.

    Article  Google Scholar 

  46. Cho SH, Whang WW. Acupuncture for vasomotor menopausal symptoms: a systematic review. Menopause. 2009;16(5):1065–73.

    Article  PubMed  Google Scholar 

  47. Chiu HY, Shyu YK, Chang PC, Tsai PS. Effects of acupuncture on menopause-related symptoms in breast cancer survivors: a meta-analysis of randomized controlled trials. Cancer Nurs. 2016;39(3):228–37.

    Article  PubMed  Google Scholar 

  48. Garcia MK, Graham-Getty L, Haddad R, et al. Systematic review of acupuncture to control hot flashes in cancer patients. Cancer. 2015;121(22):3948–58.

    Article  PubMed  Google Scholar 

  49. Sood R, Sood A, Wolf SL, et al. Paced breathing compared with usual breathing for hot flashes. Menopause. 2013;20(2):179–84.

    PubMed  Google Scholar 

  50. Carpenter JS, Burns DS, Wu J, et al. Paced respiration for vasomotor and other menopausal symptoms: a randomized, controlled trial. J Gen Intern Med. 2013;28(2):193–200.

    Article  PubMed  Google Scholar 

  51. Mann E, Smith MJ, Hellier J, et al. Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial. Lancet Oncol. 2012;13(3):309–18.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Ayers B, Smith M, Hellier J, Mann E, Hunter MS. Effectiveness of group and self-help cognitive behavior therapy in reducing problematic menopausal hot flushes and night sweats (MENOS 2): a randomized controlled trial. Menopause. 2012;19(7):749–59.

    Article  PubMed  Google Scholar 

  53. Duijts SF, Van Beurden M, Oldenburg HS, et al. Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment-induced menopausal symptoms in patients with breast cancer: results of a randomized, controlled, multicenter trial. J Clin Oncol. 2012;30(33):4124–33.

    Article  PubMed  Google Scholar 

  54. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause. 2015;22(11):1155–72; quiz 1173–1154.

    Google Scholar 

  55. Elkins G, Marcus J, Stearns V, et al. Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors. J Clin Oncol. 2008;26(31):5022–6.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Elkins GR, Fisher WI, Johnson AK, Carpenter JS, Keith TZ. Clinical hypnosis in the treatment of postmenopausal hot flashes: a randomized controlled trial. Menopause. 2013;20(3):291–8.

    PubMed  Google Scholar 

  57. Maclaughlan David S, Salzillo S, Bowe P, et al. Randomised controlled trial comparing hypnotherapy versus gabapentin for the treatment of hot flashes in breast cancer survivors: a pilot study. BMJ Open. 2013;3(9):e003138.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Lipov EG, Joshi JR, Xie H, Slavin KV. Updated findings on the effects of stellate-ganglion block on hot flushes and night awakenings. Lancet Oncol. 2008;9(9):819–20.

    Article  PubMed  Google Scholar 

  59. Lipov EG, Joshi JR, Sanders S, et al. Effects of stellate-ganglion block on hot flushes and night awakenings in survivors of breast cancer: a pilot study. Lancet Oncol. 2008;9(6):523–32.

    Article  PubMed  Google Scholar 

  60. Lipov EG, Lipov S, Joshi JR, Santucci VD, Slavin KV, Beck Vigue SG. Stellate ganglion block may relieve hot flashes by interrupting the sympathetic nervous system. Med Hypotheses. 2007;69(4):758–63.

    Article  CAS  PubMed  Google Scholar 

  61. Loprinzi CL, Diekmann B, Novotny PJ, Stearns V, Sloan JA. Newer antidepressants and gabapentin for hot flashes: a discussion of trial duration. Menopause. 2009;16(5):883–7.

    Article  PubMed  Google Scholar 

  62. Joffe H, Guthrie KA, Larson J, et al. Relapse of vasomotor symptoms after discontinuation of the selective serotonin reuptake inhibitor escitalopram: results from the menopause strategies: finding lasting answers for symptoms and health research network. Menopause. 2013;20(3):261–8.

    PubMed  PubMed Central  Google Scholar 

  63. Goetz MP, Knox SK, Suman VJ, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2007;101(1):113–21.

    Article  CAS  PubMed  Google Scholar 

  64. Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005;97(1):30–9.

    Article  CAS  PubMed  Google Scholar 

  65. Pandya KJ, Morrow GR, Roscoe JA, et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet (London, England). 2005;366(9488):818–24.

    Article  CAS  Google Scholar 

  66. Perez DG, Loprinzi CL, Barton DL, et al. Pilot evaluation of mirtazapine for the treatment of hot flashes. J Support Oncol. 2004;2(1):50–6.

    CAS  PubMed  Google Scholar 

  67. Osteoporosis prevention, diagnosis, and therapy. NIH Consens Statement. 2000;17(1):1–45.

    Google Scholar 

  68. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet (London, England). 2002;359(9321):1929–36.

    Article  Google Scholar 

  69. Runowicz CD, Leach CR, Henry NL, et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. J Clin Oncol. 2016;34(6):611–35.

    Article  CAS  PubMed  Google Scholar 

  70. Hadji P, Aapro MS, Body JJ, et al. Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann Oncol. 2011;22(12):2546–55.

    Article  CAS  PubMed  Google Scholar 

  71. Hadji P, Coleman RE, Wilson C, et al. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. Ann Oncol. 2016;27(3):379–90.

    Article  CAS  PubMed  Google Scholar 

  72. Gaillard S, Stearns V. Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management. Breast Cancer Res. 2011;13(2):205.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Gralow JR, Biermann JS, Farooki A, et al. NCCN Task Force Report: Bone Health In Cancer Care. J Natl Compr Cancer Netw. 2013;11(Suppl 3):S1–50; quiz S51.

    Article  Google Scholar 

  74. Chen Z, Maricic M, Bassford TL, et al. Fracture risk among breast cancer survivors: results from the Women’s Health Initiative Observational Study. Arch Intern Med. 2005;165(5):552–8.

    Article  PubMed  Google Scholar 

  75. Coleman RE, Rathbone E, Brown JE. Management of cancer treatment-induced bone loss. Nat Rev Rheumatol. 2013;9(6):365–74.

    Article  CAS  PubMed  Google Scholar 

  76. Kalder M, Hadji P. Breast cancer and osteoporosis - management of cancer treatment-induced bone loss in postmenopausal women with breast cancer. Breast Care. 2014;9(5):312–7.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Boonen S, Lips P, Bouillon R, Bischoff-Ferrari HA, Vanderschueren D, Haentjens P. Need for additional calcium to reduce the risk of hip fracture with vitamin d supplementation: evidence from a comparative metaanalysis of randomized controlled trials. J Clin Endocrinol Metab. 2007;92(4):1415–23.

    Article  CAS  PubMed  Google Scholar 

  78. Bonaiuti D, Shea B, Iovine R, et al. Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev. 2002;(3):Cd000333. https://doi.org/10.1002/14651858.cd000333.

  79. Jackson RD, Lacroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med. 2006;354(7):669–83.

    Article  CAS  PubMed  Google Scholar 

  80. Winters-Stone KM, Schwartz AL, Hayes SC, Fabian CJ, Campbell KL. A prospective model of care for breast cancer rehabilitation: bone health and arthralgias. Cancer. 2012;118(8 Suppl):2288–99.

    Article  PubMed  Google Scholar 

  81. Wong WW, Lewis RD, Steinberg FM, et al. Soy isoflavone supplementation and bone mineral density in menopausal women: a 2-y multicenter clinical trial. Am J Clin Nutr. 2009;90(5):1433–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Lagari VS, Levis S. Phytoestrogens for menopausal bone loss and climacteric symptoms. J Steroid Biochem Mol Biol. 2014;139:294–301.

    Article  CAS  PubMed  Google Scholar 

  83. Ishtiaq S, Fogelman I, Hampson G. Treatment of post-menopausal osteoporosis: beyond bisphosphonates. J Endocrinol Invest. 2015;38(1):13–29.

    Article  CAS  PubMed  Google Scholar 

  84. Gnant M. Role of bisphosphonates in postmenopausal women with breast cancer. Cancer Treat Rev. 2014;40(3):476–84.

    Article  CAS  PubMed  Google Scholar 

  85. Drugs.com Bisphosphonates. 2016 (December 2, 2016),

  86. Olevsky OM, Martino S. Randomized clinical trials of raloxifene: reducing the risk of osteoporosis and breast cancer in postmenopausal women. Menopause. 2008;15(4 Suppl):790–6.

    Article  PubMed  Google Scholar 

  87. Kanis JA, Johansson H, Oden A, Mccloskey EV. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone. 2009;44(6):1049–54.

    Article  CAS  PubMed  Google Scholar 

  88. Miller PD, Chines AA, Christiansen C, et al. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res. 2008;23(4):525–35.

    Article  CAS  PubMed  Google Scholar 

  89. Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res. 2008;23(12):1923–34.

    Article  CAS  PubMed  Google Scholar 

  90. Rogers A, Glover SJ, Eastell R. A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy. Bone. 2009;45(6):1044–52.

    Article  CAS  PubMed  Google Scholar 

  91. Mcclung MR, Siris E, Cummings S, et al. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene. Menopause. 2006;13(3):377–86.

    Article  PubMed  Google Scholar 

  92. Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer. 2003;98(9):1802–10.

    Article  CAS  PubMed  Google Scholar 

  93. Cummings SR, San Martin J, Mcclung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–65.

    Article  CAS  PubMed  Google Scholar 

  94. Finkelstein JS, Klibanski A, Schaefer EH, Hornstein MD, Schiff I, Neer RM. Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N Engl J Med. 1994;331(24):1618–23.

    Article  CAS  PubMed  Google Scholar 

  95. Silva BC, Costa AG, Cusano NE, Bilezikian JP. Osteoporosis: what’s new and on the horizon. Clin Obstet Gynecol. 2013;56(4):730–8.

    Article  PubMed  Google Scholar 

  96. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434–41.

    Article  CAS  PubMed  Google Scholar 

  97. Greenspan SL, Bone HG, Ettinger MP, et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med. 2007;146(5):326–39.

    Article  PubMed  Google Scholar 

  98. Tella SH, Gallagher JC. Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol. 2014;142:155–70.

    Article  CAS  PubMed  Google Scholar 

  99. Brixen K, Chapurlat R, Cheung AM, et al. Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial. J Clin Endocrinol Metab. 2013;98(2):571–80.

    Article  CAS  PubMed  Google Scholar 

  100. Mcclung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370(5):412–20.

    Article  CAS  PubMed  Google Scholar 

  101. Mcclung MR, Grauer A. Romosozumab in postmenopausal women with osteopenia. N Engl J Med. 2014;370(17):1664–5.

    Article  CAS  PubMed  Google Scholar 

  102. Siris ES, Miller PD, Barrett-Connor E, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA. 2001;286(22):2815–22.

    Article  CAS  PubMed  Google Scholar 

  103. Vescini F, Attanasio R, Balestrieri A, et al. Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis. J Endocrinol Invest. 2016;39(7):807–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. Eriksen EF, Diez-Perez A, Boonen S. Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review. Bone. 2014;58:126–35.

    Article  CAS  PubMed  Google Scholar 

  105. Mcclung M, Harris ST, Miller PD, et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med. 2013;126(1):13–20.

    Article  CAS  PubMed  Google Scholar 

  106. Avis NE, Brockwell S, Randolph JF Jr, et al. Longitudinal changes in sexual functioning as women transition through menopause: results from the Study of Women’s Health Across the Nation. Menopause. 2009;16(3):442–52.

    Article  PubMed  PubMed Central  Google Scholar 

  107. Lara LA, Useche B, Ferriani RA, et al. The effects of hypoestrogenism on the vaginal wall: interference with the normal sexual response. J Sex Med. 2009;6(1):30–9.

    Article  PubMed  Google Scholar 

  108. Nappi RE, Kokot-Kierepa M. Women’s voices in the menopause: results from an international survey on vaginal atrophy. Maturitas. 2010;67(3):233–8.

    Article  PubMed  Google Scholar 

  109. Kingsberg SA, Wysocki S, Magnus L, Krychman ML. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women’s VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J Sex Med. 2013;10(7):1790–9.

    Article  PubMed  Google Scholar 

  110. Baumgart J, Nilsson K, Stavreus-Evers A, et al. Urogenital disorders in women with adjuvant endocrine therapy after early breast cancer. Am J Obstet Gynecol. 2011;204(1):26.e21–7.

    Article  Google Scholar 

  111. Den Oudsten BL, Traa MJ, Thong MS, et al. Higher prevalence of sexual dysfunction in colon and rectal cancer survivors compared with the normative population: a population-based study. Eur J Cancer. 2012;48(17):3161–70.

    Article  Google Scholar 

  112. Carmack Taylor CL, Basen-Engquist K, Shinn EH, Bodurka DC. Predictors of sexual functioning in ovarian cancer patients. J Clin Oncol. 2004;22(5):881–9.

    Article  PubMed  Google Scholar 

  113. Stinesen Kollberg K, Waldenstrom AC, Bergmark K, et al. Reduced vaginal elasticity, reduced lubrication, and deep and superficial dyspareunia in irradiated gynecological cancer survivors. Acta Oncol. 2015;54(5):772–9.

    Article  PubMed  Google Scholar 

  114. Bachmann GA, Schaefers M, Uddin A, Utian WH. Microdose transdermal estrogen therapy for relief of vulvovaginal symptoms in postmenopausal women. Menopause. 2009;16(5):877–82.

    Article  PubMed  Google Scholar 

  115. Alexander NJ, Baker E, Kaptein M, Karck U, Miller L, Zampaglione E. Why consider vaginal drug administration? Fertil Steril. 2004;82(1):1–12.

    Article  PubMed  Google Scholar 

  116. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2006;(4):Cd001500. https://doi.org/10.1002/14651858.CD001500.pub2.

  117. Smith P. Estrogens and the urogenital tract. Studies on steroid hormone receptors and a clinical study on a new estradiol-releasing vaginal ring. Acta Obstet Gynecol Scand Suppl. 1993;157:1–26.

    CAS  PubMed  Google Scholar 

  118. Santen RJ, Pinkerton JV, Conaway M, et al. Treatment of urogenital atrophy with low-dose estradiol: preliminary results. Menopause. 2002;9(3):179–87.

    Article  PubMed  Google Scholar 

  119. Rioux JE, Devlin C, Gelfand MM, Steinberg WM, Hepburn DS. 17beta-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause. 2000;7(3):156–61.

    Article  CAS  PubMed  Google Scholar 

  120. Ayton RA, Darling GM, Murkies AL, et al. A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy. Br J Obstet Gynaecol. 1996;103(4):351–8.

    Article  CAS  PubMed  Google Scholar 

  121. Handa VL, Bachus KE, Johnston WW, Robboy SJ, Hammond CB. Vaginal administration of low-dose conjugated estrogens: systemic absorption and effects on the endometrium. Obstet Gynecol. 1994;84(2):215–8.

    CAS  PubMed  Google Scholar 

  122. Naessen T, Rodriguez-Macias K, Lithell H. Serum lipid profile improved by ultra-low doses of 17 beta-estradiol in elderly women. J Clin Endocrinol Metab. 2001;86(6):2757–62.

    CAS  PubMed  Google Scholar 

  123. Kendall A, Dowsett M, Folkerd E, Smith I. Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol. 2006;17(4):584–7.

    Article  CAS  PubMed  Google Scholar 

  124. Carter J, Goldfrank D, Schover LR. Simple strategies for vaginal health promotion in cancer survivors. J Sex Med. 2011;8(2):549–59.

    Article  PubMed  Google Scholar 

  125. Bygdeman M, Swahn ML. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas. 1996;23(3):259–63.

    Article  CAS  PubMed  Google Scholar 

  126. Caswell M, Kane M. Comparison of the moisturization efficacy of two vaginal moisturizers: pectin versus polycarbophil technologies. J Cosmet Sci. 2002;53(2):81–7.

    CAS  PubMed  Google Scholar 

  127. Loprinzi CL, Abu-Ghazaleh S, Sloan JA, et al. Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. J Clin Oncol. 1997;15(3):969–73.

    Article  CAS  PubMed  Google Scholar 

  128. Barton DL, Sloan JA, Shuster LT, et al. Impact of vaginal dehydroepiandosterone (DHEA) on vaginal symptoms in female cancer survivors: Trial N10C1 (Alliance). J Clin Oncol. 2014;32(5s):abst 9507.

    Google Scholar 

  129. Baulieu EE, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci U S A. 2000;97(8):4279–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  130. Labrie F, Luu-The V, Labrie C, et al. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev. 2003;24(2):152–82.

    Article  CAS  PubMed  Google Scholar 

  131. Labrie F, Archer D, Bouchard C, et al. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause. 2009;16(5):907–22.

    Article  PubMed  Google Scholar 

  132. Labrie F, Archer D, Bouchard C, et al. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause. 2009;16(5):923–31.

    Article  PubMed  Google Scholar 

  133. Labrie F, Archer D, Bouchard C, et al. Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration. Menopause. 2009;16(5):897–906.

    Article  PubMed  Google Scholar 

  134. Barton DL, Sloan JA, Shuster LT, et al. Physiologic effects of vaginal dehydroepiandosterone (DHEA): Alliance Trial N10C1. Supportive Care Cancer. 2014;22(Suppl 1):S1–S238, abst 0049.

    Google Scholar 

  135. Pinkerton JV, Stanczyk FZ. Clinical effects of selective estrogen receptor modulators on vulvar and vaginal atrophy. Menopause. 2014;21(3):309–19.

    Article  PubMed  Google Scholar 

  136. Kagan R, Williams RS, Pan K, Mirkin S, Pickar JH. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause. 2010;17(2):281–9.

    Article  PubMed  Google Scholar 

  137. Goldstein SR, Bachmann GA, Koninckx PR, Lin VH, Portman DJ, Ylikorkala O. Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy. Climacteric. 2014;17(2):173–82.

    Article  CAS  PubMed  Google Scholar 

  138. Bachmann GA, Komi JO. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause. 2010;17(3):480–6.

    PubMed  Google Scholar 

  139. Loprinzi CL, Balcueva EP, Liu H, et al. A phase III randomized, double-blind, placebo-controlled study of pilocarpine for vaginal dryness: North Central Cancer Treatment Group Study N04CA. J Support Oncol. 2011;9(3):105–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  140. Salvatore S, Nappi RE, Parma M, et al. Sexual function after fractional microablative CO(2) laser in women with vulvovaginal atrophy. Climacteric. 2015;18(2):219–25.

    Article  CAS  PubMed  Google Scholar 

  141. Pieralli A, Fallani MG, Becorpi A, et al. Fractional CO2 laser for vulvovaginal atrophy (VVA) dyspareunia relief in breast cancer survivors. Arch Gynecol Obstet. 2016;294(4):841–6.

    Article  CAS  PubMed  Google Scholar 

  142. Goetsch MF, Lim JY, Caughey AB. A practical solution for dyspareunia in breast cancer survivors: a randomized controlled trial. J Clin Oncol. 2015;33(30):3394–400.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  143. Goetsch MF, Lim JY, Caughey AB. Locating pain in breast cancer survivors experiencing dyspareunia: a randomized controlled trial. Obstet Gynecol. 2014;123(6):1231–6.

    Article  PubMed  Google Scholar 

  144. Buchholz S, Mogele M, Lintermans A, et al. Vaginal estriol-lactobacilli combination and quality of life in endocrine-treated breast cancer. Climacteric. 2015;18(2):252–9.

    Article  CAS  PubMed  Google Scholar 

  145. Donders G, Neven P, Moegele M, et al. Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor((R))) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study. Breast Cancer Res Treat. 2014;145(2):371–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  146. Donders G, Bellen G, Neven P, et al. Effect of ultra-low-dose estriol and lactobacilli vaginal tablets (Gynoflor(R)) on inflammatory and infectious markers of the vaginal ecosystem in postmenopausal women with breast cancer on aromatase inhibitors. Eur J Clin Microbiol Infect Dis. 2015;34(10):2023–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  147. Witherby S, Johnson J, Demers L, et al. Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study. Oncologist. 2011;16(4):424–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  148. Ekin M, Yasar L, Savan K, et al. The comparison of hyaluronic acid vaginal tablets with estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Arch Gynecol Obstet. 2011;283(3):539–43.

    Article  CAS  PubMed  Google Scholar 

  149. Miles T, Johnson N. Vaginal dilator therapy for women receiving pelvic radiotherapy. Cochrane Database Syst Rev. 2014;9:Cd007291. https://doi.org/10.1002/14651858.CD007291.pub3.

    Article  Google Scholar 

  150. Bober SL, Reese JB, Barbera L, et al. How to ask and what to do: a guide for clinical inquiry and intervention regarding female sexual health after cancer. Curr Opin Support Palliat Care. 2016;10(1):44–54.

    Article  PubMed  PubMed Central  Google Scholar 

  151. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013;20(9):888–902; quiz 903–884.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Nursing, University of Michigan, Ann Arbor, MI, USA

    Debra Barton

Authors
  1. Debra Barton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Debra Barton .

Editor information

Editors and Affiliations

  1. University of South Australia, Adelaide, SA, Australia

    Ian Olver

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Barton, D. (2018). Menopause Symptoms. In: Olver, I. (eds) The MASCC Textbook of Cancer Supportive Care and Survivorship. Springer, Cham. https://doi.org/10.1007/978-3-319-90990-5_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-90990-5_18

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-90989-9

  • Online ISBN: 978-3-319-90990-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation